GrandPharm obtained the right to commercialize BRM421,a new drug for dry eye syndrome, in mainland China, HK and Macau.

Company Name
Description GrandPharm obtained the right to develop and commercialize BRM421 in greater China. At the same time, GrandPharm subscribed for a small amount of equity of Brimbiotech
Global M&A Offices
Hollyhigh International Capital (Global M&A China)
Global M&A Advisory Advisor to the seller
Further information For further details, see: and